|
Tue, 02/06/2018 - 17:48 |
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer |
Daiichi Sankyo |
|
Wed, 01/31/2018 - 19:59 |
Further Improving Access to Therapies for Non-Small Cell Lung Cancer |
Chugai |
|
Wed, 12/20/2017 - 22:41 |
European Commission approves Roches Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer |
Rocheusa |
|
Wed, 12/20/2017 - 22:29 |
EU Follows US and Approves Chugais ALK Inhibitor "Alecensa " as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer |
Chugai |
|
Wed, 11/08/2017 - 04:55 |
Chugai's ALK Inhibitor "Alecensa " Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US |
Chugai |
|
Mon, 11/06/2017 - 21:30 |
FDA approves Roches Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer |
Rocheusa |
|
Fri, 09/08/2017 - 16:36 |
AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress |
AstraZeneca |
|
Wed, 09/06/2017 - 01:04 |
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer |
Rocheusa |
|
Mon, 06/05/2017 - 03:33 |
Phase III study showed Roches Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer |
Rocheusa |
|
Tue, 04/25/2017 - 12:56 |
Tagrisso receives full approval in the EU |
AstraZeneca |
|
Mon, 04/03/2017 - 00:06 |
Phase III ALUR study supports the use of Roches Alecensa for people with advanced ALK-positive lung cancer |
Rocheusa |
|
Wed, 03/29/2017 - 22:36 |
Phase III study shows Roches Alecensa was superior to crizotinib in a specific type of lung cancer |
Rocheusa |
|
Mon, 02/27/2017 - 02:45 |
Chugais ALK Inhibitor Alecensa |
Chugai |
|
Tue, 02/21/2017 - 02:28 |
- Alecensa is Available Now in Japan, the United States and Europe - |
Chugai |
|
Tue, 02/21/2017 - 00:16 |
Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer |
Rocheusa |
|
Fri, 02/17/2017 - 03:18 |
New Drug Application Filed for Immune Checkpoint Inhibitor, Atezolizumab |
Chugai |
|
Fri, 12/16/2016 - 13:37 |
CHMP recommends EU conditional approval of Roches Alecensa (alectinib) for people with previously treated ALK-positive NSCLC |
Rocheusa |
|
Tue, 12/06/2016 - 03:11 |
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer |
AstraZeneca |
|
Wed, 10/19/2016 - 02:37 |
FDA approves Roches cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer |
Rocheusa |
|
Tue, 10/18/2016 - 14:16 |
FDA Approves Genentechs Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer |
Genentech |
|
Sun, 10/09/2016 - 02:48 |
Roches TECENTRIQ (atezolizumab) shows significant survival advantage compared to chemotherapy regardless of PD-L1 status in a specific type of lung cancer in Phase III study |
Rocheusa |
|
Tue, 10/04/2016 - 03:02 |
US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC |
Rocheusa |
|
Sun, 10/02/2016 - 23:57 |
FDA Grants Breakthrough Therapy Designation for Genentechs Alecensa (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC |
Genentech |
|
Wed, 08/31/2016 - 22:41 |
Phase III study showed Roches cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy |
Rocheusa |
|
Tue, 08/30/2016 - 23:26 |
Phase III Study Showed Genentechs Cancer Immunotherapy TECENTRIQ |
Genentech |
